Victory Capital Management Inc. Has $66.21 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Victory Capital Management Inc. increased its position in Zoetis Inc. (NYSE:ZTS) by 8.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 338,866 shares of the company’s stock after buying an additional 26,789 shares during the period. Victory Capital Management Inc.’s holdings in Zoetis were worth $66,208,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ZTS. Aptus Capital Advisors LLC grew its stake in Zoetis by 2.2% in the third quarter. Aptus Capital Advisors LLC now owns 4,532 shares of the company’s stock valued at $885,000 after acquiring an additional 97 shares during the period. Aigen Investment Management LP acquired a new stake in Zoetis in the 3rd quarter valued at $1,935,000. Prime Capital Investment Advisors LLC increased its stake in Zoetis by 1.5% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 38,518 shares of the company’s stock valued at $7,526,000 after purchasing an additional 580 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in Zoetis by 0.7% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,112,662 shares of the company’s stock worth $217,392,000 after buying an additional 7,412 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of Zoetis in the third quarter valued at $2,218,000. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Performance

Shares of ZTS opened at $174.63 on Friday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The firm has a market cap of $78.79 billion, a PE ratio of 32.83, a PEG ratio of 2.67 and a beta of 0.90. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The stock’s fifty day moving average price is $187.61 and its two-hundred day moving average price is $180.02.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company’s revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.36 earnings per share. On average, equities research analysts forecast that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.99%. Zoetis’s payout ratio is 32.33%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Piper Sandler increased their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. BTIG Research boosted their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus increased their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Finally, JPMorgan Chase & Co. boosted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.